RankAlpha logo
Back to Rankings

GRAL

GRAILB
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
View Chart
Current thesis
The constructive case is that Q1 showed continued commercial traction: total revenue rose 28% year over year to $40.8 million, Galleri revenue rose 37% to $39.8 million, and test volume increased 50% to more than 56,000, while cash, cash equivalents, and short-term marketable securities were $823.1 million at March 31, 2026 [#8-K-2026-05-05] [#10-Q-2026-05-07].
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +5.9.
What can break
Broader reimbursement is still limited; GRAIL says it does not currently have broader Medicare or large commercial insurer coverage, which can constrain scale even if clinical interest remains solid [#10-Q-2026-05-07] [#10-K-2026-03-12].
Momentum
86
Value
41
Sentiment
55
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $64.00 · Bull $88.00 · Bear $42.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-15 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $93.20
Why
Momentum86 · Δ7d +5.9
Value41 · Δ7d +0.1
Sentiment55 · Δ7d +7.2
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
86
34% active weight
Current posture
7d trendSoftening
Δ7d
+5.9
Δ21d
+44.3
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
55
33% active weight
Current posture
7d trendImproving
Δ7d
+7.2
Δ21d
-51.8
Why this grade

Composite grade B. Momentum 85.8 / Value 41.1 / Sentiment 54.7

Fundamentals (TTM)
As of 2026-06-01
Market Cap
$2.76B
Beta
-
Shares Out
38.98M
P/E (TTM) · Derived
-6.4
P/S (TTM)
26.32
P/FCF (TTM) · Derived
-7.52
Rev YoY
+26.3%
EPS YoY
+37.5%
Gross Margin
+46.9%
Op Margin
-405.2%
Net Debt
-$763.47M
Current Ratio
7.61
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology